188 related articles for article (PubMed ID: 29512770)
1. Inhibition effects of total flavonoids from Sculellaria barbata D. Don on human breast carcinoma bone metastasis via downregulating PTHrP pathway.
Zheng X; Kang W; Liu H; Guo S
Int J Mol Med; 2018 Jun; 41(6):3137-3146. PubMed ID: 29512770
[TBL] [Abstract][Full Text] [Related]
2. [Inhibitory acting mechanism of psoralen-osthole on bone metastasis of breast cancer--an expatiation viewing from OPG/RANKL/RANK system].
Sheng L; Wu CY; Chen XF
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 May; 31(5):684-9. PubMed ID: 21812275
[TBL] [Abstract][Full Text] [Related]
3. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
4. Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.
Zhao H; Cai W; Li S; Da Z; Sun H; Ma L; Lin Y; Zhi D
Childs Nerv Syst; 2013 Jul; 29(7):1097-105. PubMed ID: 23559392
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells.
Ibaragi S; Shimo T; Iwamoto M; Hassan NM; Kodama S; Isowa S; Sasaki A
Anticancer Res; 2010 Dec; 30(12):5029-36. PubMed ID: 21187486
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of osteolytic bone metastases.
Guise TA
Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
[TBL] [Abstract][Full Text] [Related]
9. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
12. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
14. The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells.
Sterling JA; Oyajobi BO; Grubbs B; Padalecki SS; Munoz SA; Gupta A; Story B; Zhao M; Mundy GR
Cancer Res; 2006 Aug; 66(15):7548-53. PubMed ID: 16885353
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
17. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
[TBL] [Abstract][Full Text] [Related]
18. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
19. Betulinic acid, a bioactive pentacyclic triterpenoid, inhibits skeletal-related events induced by breast cancer bone metastases and treatment.
Park SY; Kim HJ; Kim KR; Lee SK; Lee CK; Park KK; Chung WY
Toxicol Appl Pharmacol; 2014 Mar; 275(2):152-62. PubMed ID: 24463094
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer cells interact with osteoblasts to support osteoclast formation.
Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]